3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
2
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Melanoma
21
Breast Neoplasms
19
Prostatic Neoplasms
12
Neuroblastoma
11
Multiple Myeloma
11
Leukemia
11
Leukemia, Myeloid, Acute
10
Lymphoma
9
Lymphoma, Non-Hodgkin
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Breast Neoplasms, Male
8
Glioblastoma
7
Ovarian Neoplasms
6
Myelodysplastic Syndromes
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasm Metastasis
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Fallopian Tube Neoplasms
5
Colorectal Neoplasms
5
Neoplasms
4
Lymphoma, Follicular
4
Leukemia, Myeloid, Chronic-Phase
4
Hodgkin Disease
4
Glioma
4
Carcinoma, Ovarian Epithelial
4
Uveal Melanoma
3
Rhabdomyosarcoma
3
Pancreatic Neoplasms
3
Medulloblastoma
3
Lung Neoplasms
3
Interventions
Cyclophosphamide
67
Dexamethasone
52
Peripheral Blood Stem Cell Transplantation
37
Lenalidomide
37
Rituximab
35
fludarabine phosphate
34
Bortezomib
30
Filgrastim
27
Etoposide
27
Cytarabine
25
Carboplatin
25
Busulfan
23
Radiotherapy
22
Melphalan
22
Gemcitabine
22
Cyclosporine
21
pomalidomide
20
fludarabine
20
Whole-Body Irradiation
20
Mycophenolic Acid
20
Paclitaxel
19
Methotrexate
18
venetoclax
17
Cisplatin
17
pembrolizumab
16
Calcium Dobesilate
16
Bevacizumab
16
Tacrolimus
14
Antilymphocyte Serum
14
Nivolumab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Recurrence
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
Clear all
NCT03615404
2021-01-28
ATTAC-P
Duke University
Phase 1
Completed
11 enrolled
7 charts